The management of chronic cough is described in evidence-based guidelines that appear to be effective for diagnosing and treating the many underlying causes of chronic cough. However, the management ...

Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment ...

Chronic cough, defined as a cough lasting at least 8 weeks, affects approximately 5% of the European population, particularly older adults and individuals with a history of smoking. In some cases, ...

Trevi Therapeutics is developing nalbuphine ER (Haduvio) for chronic cough in IPF and RCC, targeting unmet medical needs. TRVI's nalbuphine shows consistent efficacy in Phase 2 trials, but long-term ...

Camlipixant showed significant efficacy in patients with higher baseline cough frequency, despite not meeting the primary endpoint in the overall population. The trial demonstrated camlipixant's ...

Daily treatment with SC0023 yielded treatment efficacy 53.5% ± 19.2% relative to baseline in 24-hour daily cough rate and 19.5% ± 6.2% placebo effect Cough rate reduction was observed from the first ...

Chronic cough is undergoing a pivotal shift—from being viewed merely as a symptom to being recognized as a distinct disease entity. From December 4 to 6, 2025, the 5th International Cough Conference ...